RxDoctor Payments Data

Lilja Solnes, MD

Nuclear Medicine · Baltimore, MDNPI 1548309875

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,313 of the $11,339 with a category attached, or 99.8%. Progenics Pharmaceuticals, Inc. accounts for 69.5% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $5,425 and has fallen 99.5% since, to $26 in 2025. Among nuclear medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,339in general payments, 2019–2025

Across 11 payments — averaging $1030.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Progenics Pharmaceuticals, Inc.$8K
  • Novartis$3K
$478,847in research payments, 2019–2025

Across 11 payments — averaging $43,532 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$351K
  • Progenics Pharmaceuticals, Inc.$102K
  • Advanced Accelerator Applications$26K

What the payments were for

  • Consulting fees$11,313100%
  • Food & beverage$260%

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Progenics Pharmaceuticals, Inc.9$7,875
Novartis2$3,464

How this compares

$11,339 in reported general payments places this provider in the 95th percentile of 20 nuclear medicine providers in Maryland.

See all nuclear medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$579,490
Medicare patients
826
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →